“Zero Risk” of Tumorigenicity from Products Using iPS Cells Cannot Be Guaranteed at Present: PMDA’s Science Board

The Pharmaceuticals and Medical Devices Agency’s (PMDA) Science Board presented a final report of its views on the tumorigenicity of cell- and tissue-based products, including those derived from iPS cells, on August 20. The report takes into account the latest...read more